查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522290

2024 年胜肽/寡核苷酸 CDMO 全球市場報告

Peptide And Oligonucleotide CDMO Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

胜肽/寡核苷酸CDMO市場規模預計將在未來幾年快速成長。到2028年，這一數字將以12.0%的年複合成長率（CAGR）成長至33.9億美元。預測期內的成長是由個人化醫療需求不斷成長、生物技術進步、應用範圍擴大、外包增加以及慢性病負擔增加所推動的。預測期內預計的主要趨勢包括個人化治療、技術進步、品管挑戰、全球擴張以及生物製藥公司之間合作的加強。

個人化醫療的日益普及推動了勝胜肽寡核苷酸 CDMO 市場的成長。個人化醫療根據遺傳、生活方式和環境等個人特徵量身訂做醫療保健決策和治療。這一趨勢的推動因素包括基因組技術的進步、對分子層面疾病機制的更深入了解，以及對根據患者遺傳特徵和病歷客製化更有針對性和更有效的治療方案的需求。勝胜肽和寡核苷酸的合約開發和受託製造廠商（CDMO）透過生產根據個別患者的需求量身定做的治療性勝胜肽和寡核苷酸，在個人化醫療中發揮著至關重要的作用。例如，2024年2月，FDA藥物評估與研究中心（CDER）核准了16種針對罕見疾病患者的新的個人化治療方法，較前一年大幅增加。因此，個人化醫療的採用不斷增加，推動了胜肽核苷酸 CDMO 市場的發展。

胜肽和寡核苷酸 CDMO 市場的主要企業正在建立策略合作夥伴關係，以增強他們的服務、增強技術力並擴大他們的市場佔有率。勝胜肽開發和生產合作夥伴關係涉及組織之間的合作，以開發和製造基於胜肽的療法。例如，2023 年 5 月，PolyPeptide Group AG 與 Numaferm GmbH 建立了胜肽開發和生產合作夥伴關係。該合作夥伴關係利用了 Numaferm 在永續胜肽製造和生化生產平台方面的專業知識，以及 cGMP多肽製造能力和市場進入。目的是共同探索開發適合更永續的基於胜肽的原料藥生產的候選勝胜肽。

目錄

第1章執行摘要

第2章 市場特點

第3章 市場趨勢與策略

第4章宏觀經濟情景

  • 高通膨對市場的影響
  • 烏克蘭與俄羅斯戰爭對市場的影響
  • COVID-19 對市場的影響

第5章世界市場規模與成長

  • 全球胜肽核苷酸 CDMO 市場：促進因素和限制因素
    • 市場促進因素
    • 市場限制因素
  • 全球胜肽核苷酸 CDMO 市場表現：規模和成長，2018-2023 年
  • 全球胜肽核苷酸 CDMO 市場預測：規模與成長，2023-2028 年、2033 年

第6章 市場細分

  • 全球胜肽和寡核苷酸 CDMO 市場：按產品、績效和預測，2018-2023、2023-2028F、2033
  • 胜肽
  • 寡核苷酸
  • 全球胜肽和寡核苷酸 CDMO 市場：按服務類型分類的實際情況和預測，2018-2023、2023-2028F、2033
  • 合約開發
  • 契約製造
  • 全球勝胜肽和寡核苷酸 CDMO 市場：按應用、性能和預測，2018-2023、2023-2028F、2033
  • 治療藥物
  • 研究用途
  • 診斷
  • 其他應用
  • 全球胜肽和寡核苷酸 CDMO 市場：最終用戶的表現和預測，2018-2023、2023-2028F、2033
  • 生物製藥公司
  • 製藥公司
  • 研究機構
  • 學術和政府機構
  • 其他最終用戶

第 7 章 區域/國家分析

  • 全球勝胜肽和寡核苷酸 CDMO 市場：按地區、績效和預測，2018-2023、2023-2028F、2033
  • 全球勝胜肽和寡核苷酸 CDMO 市場：按國家、績效和預測，2018-2023、2023-2028F、2033

第8章亞太市場

第9章 中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章 義大利市場

第20章 西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章加拿大市場

第26章 南美洲市場

第27章 巴西市場

第28章 中東市場

第29章 非洲市場

第30章 競爭格局及公司概況

  • 胜肽/寡核苷酸CDMO市場：競爭格局
  • 勝胜肽/寡核苷酸CDMO市場：公司簡介
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Ajinomoto Co. Inc.
    • Lonza Group Ag
    • Wuxi Apptec Co. Ltd.

第31章 其他大型創新企業

  • Catalent Inc.
  • Piramal Pharma Ltd
  • Curia Global Inc.
  • Almac Group
  • Euroapi SA.
  • CordenPharma International
  • Bachem Holding AG
  • Genscript Biotech Corporation
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Ambiopharm Inc
  • ScinoPharm
  • Senn Chemicals AG
  • Aurigene Pharmaceutical Services
  • Creative Peptides

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章 重大併購

第35章前瞻性與潛力分析

第36章附錄

簡介目錄
Product Code: r18443

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that offers services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations specialize in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.

The main product types provided by peptide and oligonucleotide CDMOs are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. These CDMOs offer services including contract development and contract manufacturing. Peptides and oligonucleotides find applications in therapeutics, research applications, diagnostics, and other fields, and are utilized by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, among others.

The peptide and oligonucleotide CDMO market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide CDMO market statistics, including the peptide and oligonucleotide CDMO industry global market size, regional shares, competitors with peptide and oligonucleotide CDMO market share, detailed peptide and oligonucleotide CDMO market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide CDMO industry. These peptide and oligonucleotide CDMO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and oligonucleotide CDMO market size has grown rapidly in recent years. It will grow from $1.93 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, trends in personalized medicine, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines, highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide CDMO market size is expected to see rapid growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends expected in the forecast period include personalized therapies, technological advancements, challenges in quality control, global expansion, and increased collaboration among biopharmaceutical companies.

The peptide and oligonucleotide CDMO markets are poised for growth, driven by the increasing adoption of personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual characteristics such as genetics, lifestyle, and environment. This trend is fueled by advancements in genomic technologies, deeper insights into disease mechanisms at the molecular level, and the demand for more targeted and effective treatment options customized to patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a pivotal role in personalized medicine by producing customized therapeutic peptides and oligonucleotides to meet individual patient needs. For example, in February 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a notable increase from the previous year. Consequently, the rising adoption of personalized medicine is propelling the peptide and oligonucleotide CDMO market forward.

Key players in the peptide and oligonucleotide CDMO market are forging strategic partnerships to enrich their service offerings, enhance technological capabilities, and broaden market presence. Peptide development and production partnerships entail collaborative efforts between organizations to develop and manufacture peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG teamed up with Numaferm GmbH for peptide development and production. This collaboration harnesses PolyPeptide's cGMP manufacturing capacities and market access alongside Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The aim is to jointly explore the development of suitable peptide candidates for more sustainable production of peptide-based APIs.

In May 2024, EUROAPI strengthened its foothold in the oligonucleotide CDMO market by acquiring BianoGMP, further enhancing its capacity in Frankfurt. BianoGMP, a Germany-based CDMO specializing in providing analytical services for oligonucleotides, augments EUROAPI's capabilities, positioning it for expanded growth and innovation in the oligonucleotide segment.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Others End Users
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide And Oligonucleotide CDMO Market Characteristics

3. Peptide And Oligonucleotide CDMO Market Trends And Strategies

4. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Peptide And Oligonucleotide CDMO Market Size and Growth

  • 5.1. Global Peptide And Oligonucleotide CDMO Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Peptide And Oligonucleotide CDMO Market Segmentation

  • 6.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Peptides
  • Oligonucleotides
  • 6.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Contract Development
  • Contract Manufacturing
  • 6.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Therapeutics
  • Research Applications
  • Diagnostics
  • Other Applications
  • 6.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others End Users

7. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 8.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Peptide And Oligonucleotide CDMO Market

  • 9.1. China Peptide And Oligonucleotide CDMO Market Overview
  • 9.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Peptide And Oligonucleotide CDMO Market

  • 10.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Peptide And Oligonucleotide CDMO Market

  • 11.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • 11.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Peptide And Oligonucleotide CDMO Market

  • 12.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Peptide And Oligonucleotide CDMO Market

  • 13.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Peptide And Oligonucleotide CDMO Market

  • 14.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • 14.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Peptide And Oligonucleotide CDMO Market

  • 15.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • 15.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Peptide And Oligonucleotide CDMO Market

  • 16.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Peptide And Oligonucleotide CDMO Market

  • 17.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Peptide And Oligonucleotide CDMO Market

  • 18.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Peptide And Oligonucleotide CDMO Market

  • 19.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Peptide And Oligonucleotide CDMO Market

  • 20.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 21.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • 21.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Peptide And Oligonucleotide CDMO Market

  • 22.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Peptide And Oligonucleotide CDMO Market

  • 23.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • 23.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Peptide And Oligonucleotide CDMO Market

  • 24.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • 24.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Peptide And Oligonucleotide CDMO Market

  • 25.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • 25.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Peptide And Oligonucleotide CDMO Market

  • 26.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • 26.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Peptide And Oligonucleotide CDMO Market

  • 27.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Peptide And Oligonucleotide CDMO Market

  • 28.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • 28.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Peptide And Oligonucleotide CDMO Market

  • 29.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • 29.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 30.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape
  • 30.2. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck KGaA
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Ajinomoto Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Lonza Group Ag
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Wuxi Apptec Co. Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • 31.1. Catalent Inc.
  • 31.2. Piramal Pharma Ltd
  • 31.3. Curia Global Inc.
  • 31.4. Almac Group
  • 31.5. Euroapi SA.
  • 31.6. CordenPharma International
  • 31.7. Bachem Holding AG
  • 31.8. Genscript Biotech Corporation
  • 31.9. PolyPeptide Group
  • 31.10. Rentschler Biopharma SE
  • 31.11. Ambiopharm Inc
  • 31.12. ScinoPharm
  • 31.13. Senn Chemicals AG
  • 31.14. Aurigene Pharmaceutical Services
  • 31.15. Creative Peptides

32. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking

33. Global Peptide And Oligonucleotide CDMO Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

35. Peptide And Oligonucleotide CDMO Market Future Outlook and Potential Analysis

  • 35.1 Peptide And Oligonucleotide CDMO Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Peptide And Oligonucleotide CDMO Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Peptide And Oligonucleotide CDMO Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer